Analysis of Short-term (Operating) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Illumina Inc., short-term (operating) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
| Short-term activity ratio | Description | The company |
|---|---|---|
| Inventory turnover | An activity ratio calculated as cost of goods sold divided by inventory. | Illumina Inc. inventory turnover ratio improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
| Receivables turnover | An activity ratio equal to revenue divided by receivables. | Illumina Inc. receivables turnover ratio improved from Q1 2021 to Q2 2021 but then slightly deteriorated from Q2 2021 to Q3 2021. |
| Payables turnover | An activity ratio calculated as cost of goods sold divided by payables. | Illumina Inc. payables turnover ratio decreased from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
| Working capital turnover | An activity ratio calculated as revenue divided by working capital. | Illumina Inc. working capital turnover ratio improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average inventory processing period | An activity ratio equal to the number of days in the period divided by inventory turnover over the period. | |
| Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. | |
| Operating cycle | Equal to average inventory processing period plus average receivables collection period. | Illumina Inc. operating cycle improved from Q1 2021 to Q2 2021 but then slightly deteriorated from Q2 2021 to Q3 2021. |
| Average payables payment period | An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. | Illumina Inc. number of days of payables outstanding increased from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
| Cash conversion cycle | A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. | Illumina Inc. cash conversion cycle improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
Inventory Turnover
Illumina Inc., inventory turnover calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Cost of revenue | 338) | 324) | 329) | 323) | 268) | 205) | 240) | 290) | 259) | 265) | 262) | 278) | 256) | 255) | 244) | 236) | 232) | 228) | 230) | 200) | 181) | 176) | 175) | |||||||
| Inventory | 401) | 380) | 364) | 372) | 415) | 435) | 384) | 359) | 417) | 420) | 412) | 386) | 374) | 362) | 350) | 333) | 327) | 309) | 299) | 300) | 312) | 311) | 288) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Inventory turnover1 | 3.28 | 3.27 | 3.09 | 2.78 | 2.42 | 2.29 | 2.74 | 3.00 | 2.55 | 2.53 | 2.55 | 2.68 | 2.65 | 2.67 | 2.69 | 2.78 | 2.72 | 2.71 | 2.63 | 2.44 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 5.76 | 5.45 | 5.40 | 4.65 | 3.66 | 2.36 | 4.17 | 4.10 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 1.53 | 1.53 | 1.53 | 1.58 | 1.48 | 1.38 | 1.31 | 1.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 4.85 | 5.01 | 5.61 | 5.68 | 5.83 | 4.46 | 3.50 | 1.88 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 4.06 | 4.28 | 4.34 | 4.28 | 3.79 | 3.26 | 3.09 | 4.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 1.79 | 1.80 | 1.68 | 1.38 | 1.42 | 1.48 | 1.55 | 1.48 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 3.21 | 2.99 | 2.79 | 2.72 | 4.82 | 4.52 | 4.75 | 5.07 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 2.86 | 2.91 | 2.86 | 3.04 | 2.89 | 2.93 | 3.16 | 3.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 2.73 | 2.79 | 2.40 | 2.45 | 2.22 | 2.33 | 2.46 | 2.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 1.73 | 1.48 | 0.41 | 0.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 2.78 | 1.80 | 1.28 | 1.08 | 0.90 | 1.05 | 1.15 | 1.23 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.88 | 0.82 | 0.56 | 0.58 | 0.55 | 0.57 | 0.55 | 0.55 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 3.90 | 4.03 | 4.01 | 4.02 | 3.92 | 3.93 | 4.14 | 4.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Inventory turnover
= (Cost of revenueQ3 2021
+ Cost of revenueQ2 2021
+ Cost of revenueQ1 2021
+ Cost of revenueQ4 2020)
÷ Inventory
= (338 + 324 + 329 + 323)
÷ 401 = 3.28
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Inventory turnover | An activity ratio calculated as cost of goods sold divided by inventory. | Illumina Inc. inventory turnover ratio improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
Receivables Turnover
Illumina Inc., receivables turnover calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Revenue | 1,108) | 1,126) | 1,093) | 953) | 794) | 633) | 859) | 952) | 907) | 838) | 846) | 868) | 853) | 830) | 782) | 778) | 714) | 662) | 598) | 619) | 607) | 600) | 572) | |||||||
| Accounts receivable, net | 604) | 540) | 517) | 487) | 464) | 385) | 472) | 573) | 541) | 470) | 457) | 514) | 433) | 395) | 400) | 411) | 383) | 372) | 368) | 381) | 382) | 372) | 403) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Receivables turnover1 | 7.09 | 7.34 | 6.72 | 6.65 | 6.98 | 8.70 | 7.53 | 6.18 | 6.39 | 7.24 | 7.43 | 6.48 | 7.49 | 7.86 | 7.34 | 6.70 | 6.77 | 6.68 | 6.59 | 6.29 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 5.94 | 5.42 | 5.24 | 5.19 | 4.83 | 4.34 | 5.35 | 6.13 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 5.11 | 5.39 | 5.41 | 5.36 | 5.81 | 4.31 | 4.55 | 5.47 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 6.69 | 6.51 | 6.28 | 5.51 | 5.83 | 5.59 | 5.25 | 5.61 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 4.69 | 4.58 | 4.56 | 4.18 | 4.75 | 4.75 | 4.52 | 4.91 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 5.95 | 6.34 | 6.43 | 4.98 | 5.83 | 6.84 | 5.73 | 6.18 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 6.13 | 6.00 | 5.64 | 6.08 | 5.55 | 5.50 | 5.56 | 5.67 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 5.56 | 6.00 | 5.65 | 6.11 | 5.62 | 6.23 | 5.88 | 6.91 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 3.48 | 3.03 | 0.60 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 5.81 | 5.23 | 4.70 | 5.28 | 4.29 | 4.96 | 4.93 | 5.93 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 2.48 | 1.77 | 2.20 | 2.07 | 2.04 | 2.84 | 2.72 | 2.94 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 7.03 | 6.99 | 6.46 | 5.61 | 5.49 | 5.86 | 5.69 | 5.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Receivables turnover
= (RevenueQ3 2021
+ RevenueQ2 2021
+ RevenueQ1 2021
+ RevenueQ4 2020)
÷ Accounts receivable, net
= (1,108 + 1,126 + 1,093 + 953)
÷ 604 = 7.09
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Receivables turnover | An activity ratio equal to revenue divided by receivables. | Illumina Inc. receivables turnover ratio improved from Q1 2021 to Q2 2021 but then slightly deteriorated from Q2 2021 to Q3 2021. |
Payables Turnover
Illumina Inc., payables turnover calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Cost of revenue | 338) | 324) | 329) | 323) | 268) | 205) | 240) | 290) | 259) | 265) | 262) | 278) | 256) | 255) | 244) | 236) | 232) | 228) | 230) | 200) | 181) | 176) | 175) | |||||||
| Accounts payable | 248) | 200) | 178) | 192) | 156) | 135) | 130) | 149) | 143) | 139) | 137) | 184) | 156) | 149) | 151) | 160) | 158) | 175) | 142) | 138) | 134) | 251) | 155) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Payables turnover1 | 5.30 | 6.22 | 6.32 | 5.40 | 6.43 | 7.36 | 8.11 | 7.22 | 7.44 | 7.63 | 7.67 | 5.61 | 6.35 | 6.49 | 6.23 | 5.79 | 5.63 | 4.79 | 5.54 | 5.31 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Payables Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| Amgen Inc. | 5.41 | 4.92 | 4.40 | 4.33 | 5.01 | 4.60 | 3.60 | 3.18 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 3.89 | 2.97 | 3.69 | 4.34 | 4.65 | 3.73 | 3.23 | 3.30 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 5.20 | 5.54 | 5.29 | 4.79 | 5.46 | 5.28 | 4.55 | 5.23 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 4.46 | 4.30 | 3.75 | 3.41 | 3.53 | 3.92 | 3.97 | 3.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 9.18 | 8.70 | 8.71 | 5.42 | 9.22 | 8.93 | 7.94 | 6.56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 3.32 | 3.38 | 3.34 | 2.99 | 3.94 | 4.09 | 3.78 | 3.23 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 4.54 | 3.93 | 3.81 | 3.37 | 3.64 | 4.10 | 4.02 | 3.78 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 19.23 | 12.35 | 25.12 | 0.43 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 5.11 | 3.72 | 2.68 | 2.02 | 2.02 | 2.32 | 2.45 | 2.42 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 4.23 | 3.42 | 2.23 | 2.36 | 2.24 | 2.48 | 2.36 | 1.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 8.31 | 8.88 | 8.12 | 7.45 | 8.82 | 10.35 | 8.93 | 7.40 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Payables turnover
= (Cost of revenueQ3 2021
+ Cost of revenueQ2 2021
+ Cost of revenueQ1 2021
+ Cost of revenueQ4 2020)
÷ Accounts payable
= (338 + 324 + 329 + 323)
÷ 248 = 5.30
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Payables turnover | An activity ratio calculated as cost of goods sold divided by payables. | Illumina Inc. payables turnover ratio decreased from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
Working Capital Turnover
Illumina Inc., working capital turnover calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Current assets | 2,451) | 5,310) | 5,642) | 4,483) | 4,329) | 4,194) | 4,324) | 4,451) | 4,222) | 4,156) | 4,545) | 4,490) | 4,262) | 3,337) | 3,194) | 2,980) | 2,805) | 2,643) | 2,517) | 2,318) | 2,278) | 2,143) | 2,074) | |||||||
| Less: Current liabilities | 914) | 874) | 1,268) | 1,244) | 1,115) | 1,115) | 1,054) | 665) | 619) | 612) | 1,241) | 1,804) | 1,735) | 1,217) | 1,180) | 746) | 665) | 682) | 721) | 705) | 629) | 582) | 481) | |||||||
| Working capital | 1,537) | 4,436) | 4,374) | 3,239) | 3,214) | 3,079) | 3,270) | 3,786) | 3,603) | 3,544) | 3,304) | 2,686) | 2,527) | 2,120) | 2,014) | 2,234) | 2,140) | 1,961) | 1,796) | 1,613) | 1,649) | 1,562) | 1,593) | |||||||
| Revenue | 1,108) | 1,126) | 1,093) | 953) | 794) | 633) | 859) | 952) | 907) | 838) | 846) | 868) | 853) | 830) | 782) | 778) | 714) | 662) | 598) | 619) | 607) | 600) | 572) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Working capital turnover1 | 2.78 | 0.89 | 0.79 | 1.00 | 1.01 | 1.09 | 1.09 | 0.94 | 0.96 | 0.96 | 1.03 | 1.24 | 1.28 | 1.46 | 1.46 | 1.23 | 1.21 | 1.27 | 1.35 | 1.49 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 130.12 | — | — | — | — | — | 0.97 | 0.98 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 2.55 | 5.35 | 2.84 | 2.55 | 1.87 | 1.87 | 3.27 | 3.96 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 4.43 | 4.24 | 4.25 | 3.72 | 2.77 | 3.09 | 2.38 | 2.28 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 7.98 | 3.12 | 3.45 | 3.48 | 3.14 | 2.80 | 6.74 | 0.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 6.73 | 12.14 | 5.21 | 4.93 | 5.45 | 8.85 | 16.68 | 11.54 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 7.25 | 7.09 | 7.06 | 5.30 | 1.07 | 1.55 | 1.24 | 1.08 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 5.97 | 5.93 | 7.26 | 9.44 | 4.32 | 8.83 | 7.85 | 8.81 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 6.51 | 6.97 | 84.97 | 109.83 | 7.67 | 6.59 | 17.87 | 8.90 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 3.15 | 2.88 | 0.59 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 4.29 | 4.21 | 3.60 | 4.58 | 3.16 | 3.31 | 57.45 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1.35 | 1.29 | 1.35 | 1.20 | 1.22 | 1.92 | 1.21 | 1.41 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 2.30 | 3.10 | 3.36 | 2.76 | 2.37 | 2.69 | 3.54 | 4.48 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Working capital turnover
= (RevenueQ3 2021
+ RevenueQ2 2021
+ RevenueQ1 2021
+ RevenueQ4 2020)
÷ Working capital
= (1,108 + 1,126 + 1,093 + 953)
÷ 1,537 = 2.78
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Working capital turnover | An activity ratio calculated as revenue divided by working capital. | Illumina Inc. working capital turnover ratio improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
Average Inventory Processing Period
Illumina Inc., average inventory processing period calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Inventory turnover | 3.28 | 3.27 | 3.09 | 2.78 | 2.42 | 2.29 | 2.74 | 3.00 | 2.55 | 2.53 | 2.55 | 2.68 | 2.65 | 2.67 | 2.69 | 2.78 | 2.72 | 2.71 | 2.63 | 2.44 | — | — | — | |||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
| Average inventory processing period1 | 111 | 111 | 118 | 131 | 151 | 160 | 133 | 122 | 143 | 144 | 143 | 136 | 138 | 137 | 136 | 131 | 134 | 134 | 139 | 150 | — | — | — | |||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 63 | 67 | 68 | 79 | 100 | 155 | 88 | 89 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 239 | 239 | 239 | 231 | 247 | 265 | 279 | 300 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 75 | 73 | 65 | 64 | 63 | 82 | 104 | 194 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 90 | 85 | 84 | 85 | 96 | 112 | 118 | 75 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 204 | 203 | 217 | 265 | 257 | 247 | 236 | 247 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 114 | 122 | 131 | 134 | 76 | 81 | 77 | 72 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 128 | 125 | 128 | 120 | 126 | 124 | 116 | 119 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 134 | 131 | 152 | 149 | 164 | 156 | 148 | 155 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 211 | 247 | 897 | 2,141 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 131 | 203 | 284 | 338 | 405 | 348 | 316 | 296 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 415 | 445 | 653 | 625 | 664 | 635 | 659 | 661 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 94 | 91 | 91 | 91 | 93 | 93 | 88 | 87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 3.28 = 111
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average inventory processing period | An activity ratio equal to the number of days in the period divided by inventory turnover over the period. |
Average Receivable Collection Period
Illumina Inc., average receivable collection period calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Receivables turnover | 7.09 | 7.34 | 6.72 | 6.65 | 6.98 | 8.70 | 7.53 | 6.18 | 6.39 | 7.24 | 7.43 | 6.48 | 7.49 | 7.86 | 7.34 | 6.70 | 6.77 | 6.68 | 6.59 | 6.29 | — | — | — | |||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
| Average receivable collection period1 | 52 | 50 | 54 | 55 | 52 | 42 | 48 | 59 | 57 | 50 | 49 | 56 | 49 | 46 | 50 | 55 | 54 | 55 | 55 | 58 | — | — | — | |||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 61 | 67 | 70 | 70 | 76 | 84 | 68 | 60 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 71 | 68 | 67 | 68 | 63 | 85 | 80 | 67 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 55 | 56 | 58 | 66 | 63 | 65 | 69 | 65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 78 | 80 | 80 | 87 | 77 | 77 | 81 | 74 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 61 | 58 | 57 | 73 | 63 | 53 | 64 | 59 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 60 | 61 | 65 | 60 | 66 | 66 | 66 | 64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 66 | 61 | 65 | 60 | 65 | 59 | 62 | 53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 105 | 120 | 606 | 2,539 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 63 | 70 | 78 | 69 | 85 | 74 | 74 | 62 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 147 | 206 | 166 | 177 | 179 | 128 | 134 | 124 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 52 | 52 | 56 | 65 | 66 | 62 | 64 | 62 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 7.09 = 52
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. |
Operating Cycle
Illumina Inc., operating cycle calculation (quarterly data)
No. days
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Average inventory processing period | 111 | 111 | 118 | 131 | 151 | 160 | 133 | 122 | 143 | 144 | 143 | 136 | 138 | 137 | 136 | 131 | 134 | 134 | 139 | 150 | — | — | — | |||||||
| Average receivable collection period | 52 | 50 | 54 | 55 | 52 | 42 | 48 | 59 | 57 | 50 | 49 | 56 | 49 | 46 | 50 | 55 | 54 | 55 | 55 | 58 | — | — | — | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Operating cycle1 | 163 | 161 | 172 | 186 | 203 | 202 | 181 | 181 | 200 | 194 | 192 | 192 | 187 | 183 | 186 | 186 | 188 | 189 | 194 | 208 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Operating Cycle, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 124 | 134 | 138 | 149 | 176 | 239 | 156 | 149 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 310 | 307 | 306 | 299 | 310 | 350 | 359 | 367 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 145 | 141 | 142 | 151 | 159 | 177 | 187 | 140 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 282 | 283 | 297 | 352 | 334 | 324 | 317 | 321 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 175 | 180 | 188 | 207 | 139 | 134 | 141 | 131 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 188 | 186 | 193 | 180 | 192 | 190 | 182 | 183 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 200 | 192 | 217 | 209 | 229 | 215 | 210 | 208 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 316 | 367 | 1,503 | 4,680 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 194 | 273 | 362 | 407 | 490 | 422 | 390 | 358 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 562 | 651 | 819 | 802 | 843 | 763 | 793 | 785 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 146 | 143 | 147 | 156 | 159 | 155 | 152 | 149 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 111 + 52 = 163
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Operating cycle | Equal to average inventory processing period plus average receivables collection period. | Illumina Inc. operating cycle improved from Q1 2021 to Q2 2021 but then slightly deteriorated from Q2 2021 to Q3 2021. |
Average Payables Payment Period
Illumina Inc., average payables payment period calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Payables turnover | 5.30 | 6.22 | 6.32 | 5.40 | 6.43 | 7.36 | 8.11 | 7.22 | 7.44 | 7.63 | 7.67 | 5.61 | 6.35 | 6.49 | 6.23 | 5.79 | 5.63 | 4.79 | 5.54 | 5.31 | — | — | — | |||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
| Average payables payment period1 | 69 | 59 | 58 | 68 | 57 | 50 | 45 | 51 | 49 | 48 | 48 | 65 | 57 | 56 | 59 | 63 | 65 | 76 | 66 | 69 | — | — | — | |||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | ||||||||||||||||||||||||||||||
| Amgen Inc. | 67 | 74 | 83 | 84 | 73 | 79 | 101 | 115 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 94 | 123 | 99 | 84 | 78 | 98 | 113 | 110 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 70 | 66 | 69 | 76 | 67 | 69 | 80 | 70 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 82 | 85 | 97 | 107 | 103 | 93 | 92 | 109 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 40 | 42 | 42 | 67 | 40 | 41 | 46 | 56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 110 | 108 | 109 | 122 | 93 | 89 | 97 | 113 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 80 | 93 | 96 | 108 | 100 | 89 | 91 | 97 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 19 | 30 | 15 | 845 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 71 | 98 | 136 | 181 | 180 | 157 | 149 | 151 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 86 | 107 | 164 | 155 | 163 | 147 | 155 | 195 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 44 | 41 | 45 | 49 | 41 | 35 | 41 | 49 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 5.30 = 69
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average payables payment period | An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. | Illumina Inc. number of days of payables outstanding increased from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |
Cash Conversion Cycle
Illumina Inc., cash conversion cycle calculation (quarterly data)
No. days
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Average inventory processing period | 111 | 111 | 118 | 131 | 151 | 160 | 133 | 122 | 143 | 144 | 143 | 136 | 138 | 137 | 136 | 131 | 134 | 134 | 139 | 150 | — | — | — | |||||||
| Average receivable collection period | 52 | 50 | 54 | 55 | 52 | 42 | 48 | 59 | 57 | 50 | 49 | 56 | 49 | 46 | 50 | 55 | 54 | 55 | 55 | 58 | — | — | — | |||||||
| Average payables payment period | 69 | 59 | 58 | 68 | 57 | 50 | 45 | 51 | 49 | 48 | 48 | 65 | 57 | 56 | 59 | 63 | 65 | 76 | 66 | 69 | — | — | — | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Cash conversion cycle1 | 94 | 102 | 114 | 118 | 146 | 152 | 136 | 130 | 151 | 146 | 144 | 127 | 130 | 127 | 127 | 123 | 123 | 113 | 128 | 139 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | ||||||||||||||||||||||||||||||
| Amgen Inc. | 243 | 233 | 223 | 215 | 237 | 271 | 258 | 252 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 75 | 75 | 73 | 75 | 92 | 108 | 107 | 70 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 200 | 198 | 200 | 245 | 231 | 231 | 225 | 212 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 135 | 138 | 146 | 140 | 99 | 93 | 95 | 75 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 78 | 78 | 84 | 58 | 99 | 101 | 85 | 70 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 120 | 99 | 121 | 101 | 129 | 126 | 119 | 111 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 297 | 337 | 1,488 | 3,835 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 123 | 175 | 226 | 226 | 310 | 265 | 241 | 207 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 476 | 544 | 655 | 647 | 680 | 616 | 638 | 590 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 102 | 102 | 102 | 107 | 118 | 120 | 111 | 100 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 111 + 52 – 69 = 94
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Cash conversion cycle | A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. | Illumina Inc. cash conversion cycle improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021. |